Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Case Report: Primary Cutaneous EBV-Positive DLBCL

Publish date:: November 25, 2019

Key clinical point: A very rare case of primary cutaneous Epstein Barr virus(EBV)–positive diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) was reported in a young Chinese man.

Major finding: After six cycles of chemotherapy with cyclophosphamide, hydroxydaunorubicin, Oncovin, and prednisone, the patient achieved complete remission, with no indication of disease relapse at 35 months.

Study details: A clinical case report of a 35-year-old man with primary cutaneous EBV-positive DLBCL, NOS.

Disclosures: The study was funded by the National Natural Science Foundation of China and Guangxi Natural Science. No conflicts of interest were reported.

Citation:

Mo XL et al. J Cutan Pathol. 2019 Oct 28. doi: 10.1111/cup.13602.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,